Clinical trial
A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)
NCT06345079 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)
- Lead sponsor
- Australasian Gastro-Intestinal Trials Group
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 14, 2024
- Completion date
- June 30, 2028
- Enrollment
- 78 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.